Novasep unveils new generation protein A media

The AbSolute High Cap is based on modified silica and will capture both monoclonal and polyclonal antibodies from high titer and large volume feedstock.

According to the company, AbSolute High Cap will enable biopharmaceutical firms to minimise the cost of protein A resins.

Novasep Process president Antoine Baule said that AbSolute High Cap will help its users to increase their production efficiency and cut their costs of goods.

"We are delighted to launch this new product, which is another achievement of Novasep’s strategy to develop lean manufacturing solutions for our customers in the biopharmaceutical industry," Baule added.

Novasep Process is the biomolecule division of Novasep.